Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

August 31, 2011

Study Completion Date

March 31, 2012

Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

Temoporfin

A single dose of 0.15 mg of Temoporfin per kilogram of body weight will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes.

DEVICE

Medical diode laser emitting light at a wavelength of 652 nm. (Ceralas PDT 652, CeramOptec GmbH)

Light dose of 20 J/cm, at a rate of 100 mW/cm, will be delivered to the target tumor and margins, within 200 seconds.

Trial Locations (1)

72205

University of Arkansas for Medical Sciences, Little Rock

All Listed Sponsors
collaborator

Erasmus Medical Center

OTHER

collaborator

The Netherlands Cancer Institute

OTHER

collaborator

Biolitec Pharma Ltd.

INDUSTRY

lead

University of Arkansas

OTHER